Depression Therapy to Improve Cardiovascular Risk in HIV

Inclusion Criteria: * HIV-1 infection, documented by both: (1) any licensed rapid HIV test or HIV enzyme test kit at any time prior to study entry and (2) by at least one detectable HIV-1 antigen or at least one detectable plasma HIV-1 RNA viral load * Age equal to or greater than 18 years * Receipt of antiretroviral therapy of any kind for at least 360 days prior to screening Note: Interruptions in ART of up to 14 days total during the 360 days prior to screening are allowed * HIV-1 RNA level \< 75 copies/mL at screening NOTE: There are no CD4 cell count eligibility criteria for this trial * For women who are still of reproductive potential, a negative urine pregnancy test * Depression as defined by having a score ≥ 10 on the PHQ-9 questionnaire Exclusion Criteria: * Inability to complete written, informed consent * Incarceration at the time of any study visit * Active suicidality, as determined by the patient's HIV provider or social worker following a positive response (1, 2, or 3) to PHQ-9 Item #9 and a positive response (yes) to one or more of the three questions on the Patient Suicidality Form (with last suicide attempt within the past ten years) * Diagnosed vascular disease (documented history of angina pectoris, coronary disease, peripheral vascular disease, cerebrovascular disease, aortic aneurysm, or otherwise known atherosclerotic disease) * History of congestive heart failure, even if currently compensated * Diagnosed disease or process, besides HIV infection, associated with increased systemic inflammation (including, but not limited to, systemic lupus erythematosis, inflammatory bowel diseases, other collagen vascular diseases) Note: Hepatitis B or C co-infections are NOT exclusionary * Known or suspected malignancy requiring systemic treatment within 180 days of screening NOTE: Localized treatment for skin cancers is not exclusionary * History of Raynaud's phenomenon * History of cardiac arrhythmias or cardiomyopathy * Uncontrolled hyperthyroidism or hypothyroidism, defined as TSH values outside of the local reference range on most recent clinical assessment * History of carotid bruits * Systolic blood pressure \> 160 mmHg or diastolic blood pressure \> 110 mmHg at screening * Screening estimated glomerular filtration rate (eGFR) \< 50 mL/min/1.732 (using the 2009 CKD-EPI equation) using a serum creatinine level measured at screening * Screening glucose ≥ 140 mg/dL or hemoglobin A1c \> 8.0% * Screening total cholesterol \> 240 mg/dL * Therapy for serious medical illnesses within 14 days prior to screening Note: Therapy for serious medical illnesses that overlaps with a main study visit will result in postponement of that study visit until the course of therapy is completed; postponement outside of the allowed study visit timeframe will result in study discontinuation * Pregnancy or breastfeeding during the course of the study * Receipt of investigational agents, cytotoxic chemotherapy, systemic glucocorticoids (of any dose), or anabolic steroids at screening Note: Physiologic testosterone replacement therapy or topical steroids is not exclusionary. Inhaled/nasal steroids are not exclusionary as long as the participant is not also receiving HIV protease inhibitors * Active drug use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements * History of schizophrenia or bipolar disorder